In an implantable devices supply chain special interest group meeting hosted by Louisville, Colo.-based GHX, suppliers and providers saw different possible results that could come from formally implementing the U.S. Food and Drug Administration's final rule on Unique Device Identifiers.
Results from an online poll completed by participants at the meeting show 64 percent of suppliers saw improved order-to-cash cycle management and procure-to-pay management as areas where UDIs could have the greatest impact, while 57 percent of providers saw adverse event reporting and recall management as potential areas of improvement, according to a news release.
The final UDI rule requires device manufacturers to assign a UDI-compliant code to each covered device as well as provide any additional information to a public, FDA-run database to improve the quality of devices and begin creating a global standardized protocol for identifying devices.
More Articles on Medical Devices:
Philadelphia Pediatric Device Consortium Receives $1.5M in FDA Funding
Report: Medical Instrument and Supply Manufacturing Industry Continues to Grow
GHX Offers Supply Chain Services to Improve Billing Accuracy